Acalabrutinib in Combination with Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy in Relapsed/Refractory B-Cell Lymphoma: A Phase I/II Study of Safety, Efficacy and Immune Correlative Analysis

细胞因子释放综合征 医学 嵌合抗原受体 滤泡性淋巴瘤 不利影响 免疫学 伊布替尼 淋巴瘤 内科学 肿瘤科 免疫疗法 免疫系统 慢性淋巴细胞白血病 白血病
作者
Christina Poh,Victor A. Chow,Ryan C. Lynch,Chaitra S. Ujjani,Mazyar Shadman,Brian G. Till,Vikram Raghunathan,Edus H. Warren,Jordan Gauthier,Stephen D. Smith,Taranjit S. Gujral,Chihiro Morishima,Qian Wu,Jenna Voutsinas,Amy Sperling,Joshua Dizon,David G. Maloney,Ajay K. Gopal
出处
期刊:Blood [Elsevier BV]
卷期号:142 (Supplement 1): 2129-2129 被引量:1
标识
DOI:10.1182/blood-2023-183034
摘要

Introduction Limitations of effective CD19-targeted chimeric antigen receptor T-cell therapy (CAR-T) in relapsed/refractory (R/R) B-cell lymphoma include inability to control disease prior to CAR-T, lack of sustained remissions following CAR-T and the potential for life-threatening adverse effects such as cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS). BTK inhibitors, ibrutinib and acalabrutinib are immunomodulatory and may enhance CAR-T expansion, engraftment and tumor clearance while decreasing the frequency and severity of CRS in chronic lymphocytic leukemia (Qin, et al. J Immunother 2020). Based on this, we hypothesized that acalabrutinib, when combined with CD19-targeted CAR-T, could enhance its efficacy and safety and may also serve as an effective bridging strategy. We report the initial safety, efficacy and correlative analysis of acalabrutinib in combination with axicabtagene ciloleucel (axi-cel) in R/R B-cell lymphoma. Methods We conducted a phase I/II, open-label trial (NCT04257578) involving adult patients meeting FDA-approved criteria for axi-cel; this included patients with R/R CD19+ large B-cell (LBCL) and follicular lymphoma (FL) with measurable disease. Acalabrutinib was continuously administered at 100 mg twice daily over the 3 study phases: 1) Bridging: Starting between 3 weeks and 24 hours prior to leukapheresis until lymphodepletion (LD), 2) Cell therapy: From LD to 30 days after axi-cel infusion, 3) Maintenance: From 30 days to 1 year after axi-cel infusion or until unacceptable toxicity or disease progression (Figure 1). Axi-cel was administered per institutional practice. The primary endpoint was safety based on rates of grade ≥3 CRS or ICANS within 30 days of axi-cel infusion. We also assessed bridging success rate (defined as receipt of axi-cel without any additional required treatment), overall response rate (ORR) and complete response (CR) rate following axi-cel infusion, progression-free survival, overall survival and immune response biomarkers. Results As of July 28, 2023, 17 patients have enrolled, 14 have received axi-cel infusion and are evaluable for response to CAR-T and 3 are earlier in treatment. Fourteen patients had LBCL (12 DLBCL [4 with double/triple hit, 3 with double/triple expressor, 1 with only MYC translocation] and 2 PMBCL) and 3 had FL (Table 1). Median age was 58 (range 34-74) years, largest lesion diameter was a median of 3.75 (1.7-7.1) cm and the median number of prior regimens was 3 (range 1-5). Of LBCL patients, 6 (43%) had primary refractory disease and 5 (38%) had relapsed within 12 months of initial therapy; 4 (31%) patients had previous autologous stem cell transplant. Fourteen of 15 patients (93%) who underwent axi-cel infusion were successfully bridged from prior to leukapheresis to LD with single agent acalabrutinib and no additional therapy; 1 received added radiation. After cell infusion, 13 (93%) and 8 (57%) patients had any grade CRS and ICANS, respectively. Three (20%) patients had grade 3 ICANS which resolved with dexamethasone and anakinra or tocilizumab. No patients received prophylactic dexamethasone. No patients experienced grade ≥3 CRS or any grade hemorrhage or tachyarrhythmia. No patients discontinued acalabrutinib at any time due to toxicity, meeting an interim safety endpoint. The ORR and CR rate at day 30 post axi-cel infusion was 93% and 71%, respectively. Through post axi-cel maintenance, there were no drug holds. One of the 3 patients with partial remission (PR) at day 30 converted to CR at day 180 post infusion while 2 suffered disease progression at day 90 post axi-cel infusion. No treatment related deaths were observed by time of data cutoff. At a median follow-up of 13.8 (range 1.7-29.1) months, 10 (73%) patients are alive and 9 are progression-free. Post axi-cel cytokines peaked at a median of day 6 [median IL-6 196 pg/ml (range 20-11803), ferritin 425 ng/ml (156-2051), CRP 52.9 mg/L (7.7-239.7), Table 1]. Impact of acalabrutinib on myeloid derived suppressor cells and the immunosecretome profile are underway and will be reported at time of presentation. Conclusions Acalabrutinib successfully bridged most patients in this trial when given concurrently with axi-cel and safely maintained high CR rates. CRP and ferritin levels were typically only modestly elevated after cell infusion. Severe CRS was not observed and high-grade ICANS was uncommon.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
十个勤天完成签到,获得积分10
刚刚
小二郎的应助被张煜禾采纳,获得10
刚刚
12581发布了新的文献求助10
刚刚
优美煎蛋发布了新的文献求助10
刚刚
iuwallace发布了新的文献求助10
1秒前
milion完成签到,获得积分10
1秒前
1秒前
1秒前
YitingW发布了新的文献求助10
1秒前
1秒前
研友_nVj3yn发布了新的文献求助10
1秒前
斯文败类的应助被chuhan采纳,获得10
1秒前
gela发布了新的文献求助10
2秒前
bkagyin的应助被我爱玩原神采纳,获得10
2秒前
汉堡包的应助被Ma采纳,获得10
2秒前
Ava的应助被wu采纳,获得10
2秒前
李元发布了新的文献求助10
2秒前
zzl发布了新的文献求助10
3秒前
Maestro_S的应助被职克琪采纳,获得10
3秒前
隐形曼青的应助被职克琪采纳,获得10
3秒前
3秒前
zxy发布了新的文献求助10
3秒前
甜美的兔子完成签到,获得积分10
4秒前
4秒前
accepted完成签到,获得积分10
4秒前
传奇3的应助被愤怒的水壶采纳,获得10
4秒前
SciGPT的应助被lawliet采纳,获得10
4秒前
小零完成签到,获得积分10
4秒前
Maestro_S的应助被h11采纳,获得10
4秒前
jhlllllll发布了新的文献求助10
4秒前
董文强发布了新的文献求助10
5秒前
5秒前
5秒前
清风明月发布了新的文献求助10
5秒前
迷了路的猫完成签到,获得积分10
6秒前
6秒前
jonghuang发布了新的文献求助10
9秒前
赘婿的应助被window1000采纳,获得10
9秒前
贤君发布了新的文献求助10
9秒前
10秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
What Else Can I Tell You?: A Pragmatic Study of English Rhetorical Questions as Discursive and Argumentative Acts 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8164445
求助须知:如何正确求助?哪些是违规求助? 9558283
关于积分的说明 21744871
捐赠科研通 7754979
什么是DOI,文献DOI怎么找? 3428582
关于科研通互助平台的介绍 2553119
邀请新用户注册赠送积分活动 2473142